Results 41 to 50 of about 245,728 (306)

CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development

open access: yesViruses, 2018
The clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein 9 (Cas9) technology is revolutionizing genome editing approaches.
Arinze Okoli   +3 more
doaj   +1 more source

Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a

open access: yesScientific Reports, 2022
The CRISPR-Cas system is widely used for genome editing of cultured cells and organisms. The discovery of a new single RNA-guided endonuclease, CRISPR-Cas12a, in addition to the conventional CRISPR-Cas9 has broadened the number of editable target sites ...
Riki Ishibashi   +4 more
doaj   +1 more source

CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis [PDF]

open access: yes, 2016
Retinoblastoma is a pediatric eye tumor in which bi-allelic inactivation of the Retinoblastoma 1 (RB1) gene is the initiating genetic lesion. Although recently curative rates of retinoblastoma have increased, there are at this time no molecular targeted ...
Boel, Annekatrien   +12 more
core   +2 more sources

Prevention of Avian Retrovirus Infection in Chickens Using CRISPR-Cas9 Delivered by Marek’s Disease Virus

open access: yesMolecular Therapy: Nucleic Acids, 2020
Reticuloendotheliosis virus (REV) is an avian retrovirus that causes an oncogenic, immunosuppressive, and runting-stunting syndrome in avian hosts. The co-infection of REV and Marek’s disease virus (MDV), an oncogenic herpesvirus in chickens, further ...
Kai Li   +12 more
doaj   +1 more source

High-Resolution Analysis of the Efficiency, Heritability, and Editing Outcomes of CRISPR/Cas9-Induced Modifications of NCED4 in Lettuce (Lactuca sativa). [PDF]

open access: yes, 2018
CRISPR/Cas9 is a transformative tool for making targeted genetic alterations. In plants, high mutation efficiencies have been reported in primary transformants. However, many of the mutations analyzed were somatic and therefore not heritable.
Bertier, Lien D   +5 more
core   +2 more sources

Rapid Assessment of CRISPR Transfection Efficiency and Enrichment of CRISPR Induced Mutations Using a Dual-Fluorescent Stable Reporter System

open access: yesFrontiers in Genome Editing, 2022
The nuclease activity of the CRISPR-Cas9 system relies on the delivery of a CRISPR-associated protein 9 (Cas9) and a single guide RNA (sgRNA) against the target gene.
Karim E. Shalaby   +6 more
doaj   +1 more source

Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases. [PDF]

open access: yes, 2016
We examined the efficiency, specificity, and mutational signatures of zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 systems designed to
Bjurström, Carmen F   +11 more
core   +3 more sources

Rewriting Human History and Empowering Indigenous Communities with Genome Editing Tools. [PDF]

open access: yes, 2020
Appropriate empirical-based evidence and detailed theoretical considerations should be used for evolutionary explanations of phenotypic variation observed in the field of human population genetics (especially Indigenous populations). Investigators within
Fox, Keolu   +2 more
core   +2 more sources

Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides

open access: yesGenome Biology, 2020
Background CRISPR-Cas9 has been developed as a therapeutic agent for various infectious and genetic diseases. In many clinically relevant applications, constitutively active CRISPR-Cas9 is delivered into human cells without a temporal control system ...
Yan-ru Cui   +13 more
doaj   +1 more source

Using the CRISPR/Cas9 system to understand neuropeptide biology and regulation [PDF]

open access: yes, 2016
Funding was provided by a Wellcome Trust ISSF starting grant (105625/Z/14/Z), Medical Research Scotland (PhD-719-2013), GW Pharmaceuticals (PhD-719-2013 - S.5242.001) and the BBSRC (BB/J012343/1).Peer reviewedPublisher ...
Hay, Elizabeth A   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy